Regeneron Pharmaceuticals Inc. (REGN) Financial Statements (2026 and earlier)

Company Profile

Business Address 777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
State of Incorp. NY
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,6059,01310,8457,7425,6953,587
Cash and cash equivalent3,1182,4882,7303,1062,8862,194
Short-term investments5,4876,5248,1154,6362,8091,393
Restricted cash and investments61    
Receivables5,7416,2125,6675,3296,0373,112
Inventory, net of allowances, customer advances and progress billings3,2013,0872,5812,4021,9511,917
Inventory3,2013,0872,5812,4021,9511,917
Other undisclosed current assets4693483874113321,164
Total current assets:18,02218,66119,47915,88414,0159,779
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 577591606620631646
Operating lease, right-of-use asset 24621778   
Long-term investments and receivables10,2958,9005,3976,5926,8383,136
Long-term investments10,2958,9005,3976,5926,8383,136
Intangible asset, including goodwill, after accumulated amortization1,2571,1491,039916  
Intangible asset, excluding goodwill, after accumulated amortization1,2571,1491,039916  
Restricted cash and investments   8   
Deferred income tax assets4,0773,3142,5751,724877859
Other noncurrent assets1,8211,136444336223168
Other undisclosed noncurrent assets4,2643,7913,4553,1432,8512,576
Total noncurrent assets:22,53719,09913,60113,33011,4207,384
TOTAL ASSETS:40,55937,75933,08029,21525,43517,163
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,8762,5272,3582,0742,2071,522
Taxes payable✕✕✕✕✕32620
Employee-related liabilities✕✕✕✕✕441466
Accounts payable939790607589564476
Accrued liabilities 1,6441,4251,2851,135384330
Other undisclosed accounts payable and accrued liabilities 294312466350492231
Deferred revenue553628459478442 
Debt    720 
Other liabilities      122
Other undisclosed current liabilities9397906075895641,053
Total current liabilities:4,3683,9443,4233,1413,9332,697
Noncurrent Liabilities
Long-term debt and lease obligation2,7062,7042,7032,7011,9802,696
Long-term debt, excluding current maturities1,9861,9841,9831,9811,9801,979
Finance lease, liability 720720720720 717
Liabilities, other than long-term debt2,2281,757981708754 
Deferred revenue2091861277073 
Other liabilities2,0191,571854638680 
Other undisclosed noncurrent liabilities      745
Total noncurrent liabilities:4,9334,4623,6843,4092,7343,441
Total liabilities:9,3028,4067,1076,5516,6666,138
Equity
Equity, attributable to parent, including:31,25729,35425,97322,66418,76911,025
Treasury stock, value(18,613)(15,167)(12,560)(10,353)(8,261)(6,613)
Additional paid in capital13,99512,85611,3549,9498,0886,716
Accumulated other comprehensive income (loss)78(8)(81)(239)(26)29
Retained earnings35,79731,67327,26023,30718,96810,893
Other undisclosed equity, attributable to parent000000
Total equity:31,25729,35425,97322,66418,76911,025
TOTAL LIABILITIES AND EQUITY:40,55937,75933,08029,21525,43517,163

Income Statement (P&L) ($ in millions)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues14,34314,20213,11712,17316,0728,497
Cost of revenue(2,215)(2,125)(2,000)(1,726)(2,392)(840)
Cost of product and service sold (173)(126)(102)(259)(457)(39)
Gross profit:12,12812,07711,11710,44713,6807,658
Operating expenses(8,550)(8,086)(7,070)(5,708)(4,733)(4,081)
Other operating income (expense), net10(53)29046280
Other undisclosed operating income (loss)(10)53(2)(90)(46)(280)
Operating income:3,5783,9914,0474,7398,9473,577
Nonoperating income1,653789152120379234
Other nonoperating income1,697844225179436291
Interest and debt expense(44)(55)(73)(59)(57)(57)
Other undisclosed income from continuing operations before equity method investments, income taxes      57
Income from continuing operations before equity method investments, income taxes:5,1874,7254,1264,7999,2693,810
Other undisclosed income from continuing operations before income taxes4455735957 
Income from continuing operations before income taxes:5,2314,7804,1994,8599,3263,810
Income tax expense(726)(367)(246)(520)(1,251)(297)
Income from continuing operations:4,5054,4133,9544,3388,0753,513
Income before gain (loss) on sale of properties:✕✕✕✕✕8,0753,513
Net income available to common stockholders, diluted:4,5054,4133,9544,3388,0753,513

Comprehensive Income ($ in millions)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income:4,5054,4133,9544,3388,0753,513
Other comprehensive income (loss)   158(213)(56) 
Comprehensive income:4,5054,4134,1124,1268,0203,513
Other undisclosed comprehensive income (loss), net of tax, attributable to parent8573   8
Comprehensive income, net of tax, attributable to parent:4,5904,4864,1124,1268,0203,521

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: